Chemiluminescent Immunoassay (CLIA)
May aid as a marker for prostate cancer. Do not use as a screening procedure as PSA has been observed in patient's with benign prostatic hypertrophy. Diagnostic PSA (DPSA) should be utilized for patients with a diagnosis of prostate cancer.
MALE: Age 0 - 49 yrs: 0 - 2.5 ng/mL, Age 50 - 59 yrs: 0 - 3.5 ng/mL, Age 60 - 69 yrs: 0 - 4.5 ng/mL, Age 70 - 150 yrs: 0 - 6.5 ng/mL. FEMALE: Age 0 - 150 yrs: 0 - 0.1 ng/mL.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
- PROSTATE SPECIFIC ANTIGEN
- PROSTATE SPECIFIC AG, DIAGNOS
- NATIONAL PSA SCREEN
Collect specimen in an SST or red top tube. Centrifuge, aliquot serum into plastic vial. Refrigerate up to 8 hours or freeze for longer storage. Transport to MLabs as a frozen aliquot. Please indicate whether test is being orderd for Screening (PSA) or Diagnostic (DPSA) purposes.
Prostate Specific Antigen is a more sensitive marker of prostatic adenocarcinoma than Prostatic Acid Phosphatase.